Immune checkpoint inhibitor-induced eosinophilic fasciitis: an international retrospective and pharmacovigilance analysis by the EADV “Dermatology for Cancer patients” Task Force
free, with no need for new therapeutic interventions.Include pictures documenting evolution.Results: The case described reinforces the relevance of ipilimumab as a component of a therapeutic strategy in the management of metastatic melanoma, demonstrating its ability to induce longlasting responses in specific subgroups of patients.Studies have shown that complete response (CR) rates to ipilimumab alone range from 6.5% to 10%, and these responses are often associated with prolonged benefits in disease-free progression (PFS) and overall survival (OS), especially in patients who tolerate re-exposure to treatment.Conclusions: There is a positive impact of ipilimumab in the management of advanced melanoma.The sustained response and disease control over more than a decade reflect the importance of tailoring therapeutic strategies, considering the patient's clinical profile.
Authors
- Kara Heelan (ORCID: https://orcid.org/0000-0001-9527-0844)
- Mariëtte Labots (ORCID: https://orcid.org/0000-0002-7095-1771)
- Michael R. Ardern‐Jones (ORCID: https://orcid.org/0000-0003-1466-2016)
- J van der Laken
- Dimitra Koumaki (ORCID: https://orcid.org/0000-0001-7074-2374)
- F. Dezoteux (ORCID: https://orcid.org/0000-0001-8930-1042)
- Ángel M. Mayor (ORCID: https://orcid.org/0000-0002-7705-837X)
- V. Sibaud
- Alexandre Olivier Gérard (ORCID: https://orcid.org/0000-0001-6591-6966)
- Yannick S. Elshot (ORCID: https://orcid.org/0000-0001-7148-2439)
- Damien Giacchero
- Jesse Hirner
- Tristan V.M. Bruijn
- W. Van Binsbergen
- M. Labat
- R. Valérian
Institutions
- University of Nebraska–Lincoln (US)
- Royal Marsden NHS Foundation Trust (GB)
- Hospital Universitario La Paz (ES)
- Saint Louis University Hospital (US)
- University of Nebraska System (US)
- University Hospital Southampton NHS Foundation Trust (GB)
- Centre Hospitalier Universitaire de Nice (FR)
- Laboratoire de PhysioMédecine Moléculaire (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Institut Claudius Regaud (FR)
- University Hospital of Heraklion (GR)
- Hôpital Saint-Louis (FR)
- Amsterdam University Medical Centers (NL)
- Centre Antoine Lacassagne (FR)
- Hôpital Claude Huriez (FR)
- University of Southampton (GB)
- University of Nebraska Medical Center (US)
- University of Amsterdam (NL)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100561
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00